Advertisement
Advertisement

SVRA

SVRA logo

Savara Inc.

5.25
USD
Sponsored
-0.04
-0.66%
Mar 26, 15:59 UTC -4
Closed
exchange

After-Market

5.20

-0.04
-0.84%

SVRA Earnings Reports

Positive Surprise Ratio

SVRA beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.13
Implied change from Q4 25 (Revenue/ EPS)
--
/
--
Implied change from Q1 25 (Revenue/ EPS)
--
/
+8.33%

Savara Inc. earnings per share and revenue

On Mar 13, 2026, SVRA reported earnings of -0.13 USD per share (EPS) for Q4 25, missing the estimate of -0.12 USD, resulting in a -8.15% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.32% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
logo
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
logo
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
logo
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
logo
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-
Surprise
-
logo
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
logo
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
logo
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
logo
electroCore, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.34
Surprise
+18.15%
FAQ
For Q4 2025, Savara Inc. reported EPS of -$0.13, missing estimates by -8.15%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.32%, changed from $5.32 before the earnings release to $5.25 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 8 analysts, Savara Inc. is expected to report EPS of -$0.13 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement